Latest news with #ParseBiosciences
National Post
10-07-2025
- Health
- National Post
Parse-Enabled Study Maps Neuronal Pathways with Potential Implications for Neurodegenerative Disease Research
Article content SEATTLE — Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced a groundbreaking study published in the journal Science that utilized Parse's single cell technology to uncover how signaling pathways drive the formation of diverse neuron cell subtypes. By linking specific signals to cell fate outcomes, this research provides a powerful framework for generating defined cell types in vitro, which has broad relevance to human biology, disease, and therapeutic development. Article content Principle investigators Dr. Barbara Treutlein, Head of the Quantitative Development Biology Lab at ETH Zurich, and Dr. Gray Camp, Group Leader at the Institute of Human Biology at Roche, led the experiment. Article content Through an elegantly designed screening approach spanning 480 morphogens across 700,000 cells, the research team was able to explore how different morphogens interact with pro-neural transcription factors, thereby generating pure populations of different types of neurons from pluripotent stem cells. This work will guide and enable the neuroscience research community to direct and develop pure neuronal cell populations which will help expand our understanding of cell types and cell interactions implicated in neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS. 'We were genuinely surprised by the diversity of neurons that we generated, and the data allowed us to develop algorithms to learn how this diversity can arise,' states Treutlein. 'Parse Biosciences' technology delivered the flexibility, scale, and quality to help us explore these complex cellular processes at a deeper level.' Article content 'The beauty of this work is that the underlying strategy, methods, and analyses can be adapted to program and explore any cell type and state, across organ systems and species,' states Camp. 'We are excited about what Parse's technology has enabled for this study.' Article content 'We are thrilled to support this highly impactful study from Dr. Treutlein's and Dr. Camp's Labs and are eager to see how their findings inform the wider research community,' states Dr. Charlie Roco, Chief Technology Officer of Parse Biosciences. Article content About Parse Biosciences Article content Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. Article content With technology developed at the University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $100 million in capital and is used by 3,000 customers across the world. Its growing portfolio of products includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and a solution for data analysis, Trailmaker™. Article content Article content Article content Article content
Business Wire
10-07-2025
- Health
- Business Wire
Parse-Enabled Study Maps Neuronal Pathways with Potential Implications for Neurodegenerative Disease Research
SEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced a groundbreaking study published in the journal Science that utilized Parse's single cell technology to uncover how signaling pathways drive the formation of diverse neuron cell subtypes. By linking specific signals to cell fate outcomes, this research provides a powerful framework for generating defined cell types in vitro, which has broad relevance to human biology, disease, and therapeutic development. 'Parse Biosciences' technology delivered the flexibility, scale, and quality to help us explore these complex cellular processes at a deeper level," states Barbara Treutlein, Head of the Quantitative Development Biology Lab at ETH Zurich. Principle investigators Dr. Barbara Treutlein, Head of the Quantitative Development Biology Lab at ETH Zurich, and Dr. Gray Camp, Group Leader at the Institute of Human Biology at Roche, led the experiment. Through an elegantly designed screening approach spanning 480 morphogens across 700,000 cells, the research team was able to explore how different morphogens interact with pro-neural transcription factors, thereby generating pure populations of different types of neurons from pluripotent stem cells. This work will guide and enable the neuroscience research community to direct and develop pure neuronal cell populations which will help expand our understanding of cell types and cell interactions implicated in neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS. 'We were genuinely surprised by the diversity of neurons that we generated, and the data allowed us to develop algorithms to learn how this diversity can arise,' states Treutlein. 'Parse Biosciences' technology delivered the flexibility, scale, and quality to help us explore these complex cellular processes at a deeper level.' 'The beauty of this work is that the underlying strategy, methods, and analyses can be adapted to program and explore any cell type and state, across organ systems and species,' states Camp. 'We are excited about what Parse's technology has enabled for this study.' 'We are thrilled to support this highly impactful study from Dr. Treutlein's and Dr. Camp's Labs and are eager to see how their findings inform the wider research community,' states Dr. Charlie Roco, Chief Technology Officer of Parse Biosciences. About Parse Biosciences Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. With technology developed at the University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $100 million in capital and is used by 3,000 customers across the world. Its growing portfolio of products includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and a solution for data analysis, Trailmaker™. Parse Biosciences is based in Seattle's vibrant South Lake Union district, where it recently expanded into a new headquarters and state-of-the-art laboratory. To learn more, please visit
Business Wire
08-07-2025
- Health
- Business Wire
Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella
SEATTLE--(BUSINESS WIRE)--The Vanderbilt University Medical Center and Parse Biosciences today announced a strategic collaboration to generate a single cell atlas focused on understanding the diversity of plasmablasts – early immune cell clonotypes critical in the formation of neutralizing antibodies – for measles, mumps and rubella. This effort aims to build the most comprehensive understanding of the formation of neutralizing antibodies to the vaccine and to identify the dominant and effective antibodies to these infectious agents. 'This collaboration enables us to create the largest single cell atlas of neutralizing plasmablasts ever assembled,' states James Crowe, Director of Vanderbilt's Center for Antibody Therapeutics. Share Dr. James Crowe, Director of Vanderbilt's Center for Antibody Therapeutics, will lead the development of the large-scale immune cell study. 'This collaboration enables us to create the largest single cell atlas of neutralizing plasmablasts ever assembled,' states Crowe. 'By sequencing and mapping tens of millions of B cell receptors, we can uncover the most potent antibody lineages, accelerating antibody discovery and informing vaccine design. These insights give us a critical edge in responding to both emerging infectious threats and optimizing existing immunization strategies." Leveraging Parse's Evercode chemistry, the GigaLab can rapidly produce large single cell datasets, sequencing these immune cells with exceptional granularity at scale. 'We are thrilled to be working with Dr. James Crowe and the Vanderbilt team on such an exciting project,' says Dr. Charlie Roco, Chief Technology Officer at Parse Biosciences. 'The speed and scale achieved with the GigaLab will enable us to sequence unprecedented numbers of immune cells present after exposure to these viral antigens. In addition to better understanding the immune diversity, clonal expansion, and antigen specificity of antibodies across a number of diverse patients, these findings may also identify novel therapeutic antibodies.' About Parse Biosciences Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. With technology developed at the University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $100 million in capital and is used by 3,000 customers across the world. Its growing portfolio of products includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and a solution for data analysis, Trailmaker™. Parse Biosciences is based in Seattle's vibrant South Lake Union district, where it recently expanded into a new headquarters and state-of-the-art laboratory. To learn more, please visit
National Post
08-07-2025
- Health
- National Post
Vanderbilt Selects Parse Biosciences GigaLab to Generate Atlas of Early Neutralizing Antibodies to Measles, Mumps, and Rubella
Article content Researchers aim to discover dominant subtypes of plasmablasts initiating from the MMR vaccine in order to develop neutralizing antibody candidate therapies Article content SEATTLE — The Vanderbilt University Medical Center and Parse Biosciences today announced a strategic collaboration to generate a single cell atlas focused on understanding the diversity of plasmablasts – early immune cell clonotypes critical in the formation of neutralizing antibodies – for measles, mumps and rubella. This effort aims to build the most comprehensive understanding of the formation of neutralizing antibodies to the vaccine and to identify the dominant and effective antibodies to these infectious agents. Article content Dr. James Crowe, Director of Vanderbilt's Center for Antibody Therapeutics, will lead the development of the large-scale immune cell study. Article content 'This collaboration enables us to create the largest single cell atlas of neutralizing plasmablasts ever assembled,' states Crowe. 'By sequencing and mapping tens of millions of B cell receptors, we can uncover the most potent antibody lineages, accelerating antibody discovery and informing vaccine design. These insights give us a critical edge in responding to both emerging infectious threats and optimizing existing immunization strategies.' Article content Leveraging Parse's Evercode chemistry, the GigaLab can rapidly produce large single cell datasets, sequencing these immune cells with exceptional granularity at scale. Article content 'We are thrilled to be working with Dr. James Crowe and the Vanderbilt team on such an exciting project,' says Dr. Charlie Roco, Chief Technology Officer at Parse Biosciences. 'The speed and scale achieved with the GigaLab will enable us to sequence unprecedented numbers of immune cells present after exposure to these viral antigens. In addition to better understanding the immune diversity, clonal expansion, and antigen specificity of antibodies across a number of diverse patients, these findings may also identify novel therapeutic antibodies.' Article content About Parse Biosciences Article content Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. Article content With technology developed at the University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $100 million in capital and is used by 3,000 customers across the world. Its growing portfolio of products includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and a solution for data analysis, Trailmaker™. Article content Article content Article content Article content
Business Upturn
26-06-2025
- Health
- Business Upturn
Parse Biosciences GigaLab to Support Mount Sinai Researchers in Generating One of the Largest Alzheimer's and Parkinson's Single Cell Datasets
Seattle, United States: Parse Biosciences today announced their commitment to support researchers from the Icahn School of Medicine at Mount Sinai in generating one of the largest single cell datasets focused on understanding alternative splicing events in the cells of Alzheimer's and Parkinson's patients. The study's initial phase will analyze transcriptomic profiles from more than 10 million cells derived from more than 1,000 peripheral blood mononuclear cell (PBMC) samples of patients with neurodegenerative conditions. The data amassed from these analyses will lay the foundation for discoveries that could transform how these diseases are understood, detected, and treated. 'Historical research in neurodegenerative disease has focused on the genomic underpinnings for disease diagnoses, but few have looked at the post transcriptional events that may be further driving pathology and progression of disease,' said Towfique Raj, PhD, principal investigator in the laboratory for functional genomics and core faculty member of the Ronald M. Loeb Center for Alzheimer's Disease at Mount Sinai, who will lead this study. 'We're excited to be able to look at alternative splicing events in single cells at scale to determine alternative contributors to disease onset, progression and severity. Studies of this scale are critical to the development of foundational models to help us better understand neurodegenerative disease.' Dr. Raj's research team at Mount Sinai is dedicated to understanding the molecular mechanisms of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and ALS (amyotrophic lateral sclerosis). For this study, the Mount Sinai team is working to conduct high-throughput profiling on banked PBMCs donated by patients with confirmed Alzheimer's disease or Parkinson's disease diagnoses. The researchers expect to profile more than 1,000 samples in order to capture single cell whole transcriptome repertoire data on them. The samples that have been prepared at Mount Sinai will then be sent to Parse GigaLab, a state-of-the-art facility purpose-built for the generation of massive-scale single cell RNA sequencing datasets. Leveraging Parse's Evercode chemistry, the GigaLab can rapidly produce large single cell datasets with exceptional quality. 'We are incredibly excited to bring the power of GigaLab to elevate the impactful work the Raj Lab has been driving,' says Dr. Charlie Roco, Chief Technology Officer at Parse Biosciences. 'The speed and scale achieved with the GigaLab truly helps to accelerate research and get us to insights faster than we ever have before.' About Parse Biosciences Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. With technology developed at the University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $100 million in capital and is used by over 2,500 customers across the world. Its growing portfolio of products includes Evercode™ Whole Transcriptome, Evercode™ TCR, Evercode™ BCR, Gene Select, and a solution for data analysis, Trailmaker™. Parse Biosciences is based in Seattle's vibrant South Lake Union district, where it recently expanded into a new headquarters and state-of-the-art laboratory. To learn more, please visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
